Institute News

November 14, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database.   Neurotech has partnered with Prevent Blindness to sponsor an online event with a focus on MacTel Type 2.  This free webinar will take place on November 14, 2024, 6:00 – 7:00 pm Eastern Time.  For… View Article

LMRI would like to share the following press release from Neurotech Pharmaceuticals about the BLA for NT-501 as a treatement for MacTel: Cumberland, R.I., November 8, 2024 (BUSINESS WIRE) – Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, today announced that the U.S. Food and Drug Administration (FDA), has extended… View Article

June 20, 2024 LMRI would like to share the news that Neurotech has received Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a treatment for MacTel.  For more information, please refer to the Neurotech press release.  For questions about NT-501, we encourage you to refer to the Patients section of the… View Article

April 29, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database.   This post will explain some (but not all) of the imaging exams that your eye doctor may perform during a screening or follow up visit for MacTel, and possible results of those tests. Further tests,… View Article

March 6, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database.   LMRI is conducting the SAFE study (Phase 2a Study of the Effect of Serine Supplementation and Fenofibrate Treatment on Serum Deoxysphinganine Levels in Patients with Macular Telangiectasia (MacTel) Type 2). The study aims to determine… View Article

February 6, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database.   The MacTel Project is an international research effort whose goal is to find the causes of, and treatments for, macular telangiectasia type 2.  The project was established in 2004 and is overseen by the Lowy… View Article

November 2, 2022 Neurotech Pharmaceuticals, Inc. announces positive Phase 3 topline results for NT-501 implant in macular telangiectaisa type 2 (MacTel).  (Cumberland, RI) Clinically relevant and statistically significant primary results with the NT-501 implant demonstrated change in the rate of progression of disease in Macular telangiectasia type 2 (MacTel) patients in two pivotal Phase 3… View Article

LOWY MEDICAL RESEARCH INSTITUTE – LMRI This past year has surely been an interesting and challenging one.  We hope that you and your family, friends, neighbors, and coworkers were able to weather the events safely. Despite the many challenges presented by the pandemic, all our investigators and clinical sites are to be commended for continuing… View Article

September 21, 2020 Neurotech Pharmaceuticals, with support from the Lowy Medical Research Institute, is conducting a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2.  This is a multi-center trial, with clinical sites in the United States, Europe, and Australia. The clinical trial tests whether CNTF, a small… View Article

March 24, 2020 The rapid spread of COVID-19 has disrupted many standard clinical operations, including the LMRI/Neurotech Phase 1, 2, and 3 clinical trials testing CNTF in MacTel. If you have questions regarding upcoming appointments or other study-related questions and are having trouble reaching the study team, please use our contact page and we will assist… View Article